Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Gains from Sales and Divestitures (2017 - 2023)

Historic Gains from Sales and Divestitures for Ani Pharmaceuticals (ANIP) over the last 7 years, with Q1 2023 value amounting to $235000.0.

  • Ani Pharmaceuticals' Gains from Sales and Divestitures rose 4596.27% to $235000.0 in Q1 2023 from the same period last year, while for Mar 2023 it was $235000.0, marking a year-over-year increase of 4596.27%. This contributed to the annual value of $245000.0 for FY2022, which is 9600.0% up from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Gains from Sales and Divestitures of $235000.0 as of Q1 2023, which was up 4596.27% from $245000.0 recorded in Q4 2022.
  • In the past 5 years, Ani Pharmaceuticals' Gains from Sales and Divestitures registered a high of $245000.0 during Q4 2022, and its lowest value of $34000.0 during Q1 2021.
  • Over the past 5 years, Ani Pharmaceuticals' median Gains from Sales and Divestitures value was $125500.0 (recorded in 2021), while the average stood at $126937.5.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first tumbled by 3061.22% in 2021, then soared by 37352.94% in 2022.
  • Ani Pharmaceuticals' Gains from Sales and Divestitures (Quarter) stood at $42000.0 in 2019, then surged by 202.38% to $127000.0 in 2020, then decreased by 1.57% to $125000.0 in 2021, then soared by 96.0% to $245000.0 in 2022, then fell by 4.08% to $235000.0 in 2023.
  • Its Gains from Sales and Divestitures was $235000.0 in Q1 2023, compared to $245000.0 in Q4 2022 and $234000.0 in Q3 2022.